For how we live.
In a 462-person phase 3 trial, a synthesised copy of semaglutide, HD1916, cut body weight 13.1% over 44 weeks against 14.4% for the branded drug — inside the margin set for calling them equivalent.
In a phase 3 trial, tambotatug pelitecan extended median survival to 13.3 months versus 9.4 on standard chemotherapy — but the trial was open-label and run entirely in China.
In the LAIS trial, more patients given intravenous loberamisal recovered with little or no disability at 90 days — a rare positive result in a field littered with failed neuroprotectants.
A Chinese birth cohort of 1,278 pairs found higher prenatal temperatures and heatwaves — especially in the second trimester — tracked with higher creatinine and urea in early childhood.
A prospective, quasi-experimental study links the air-quality gains after China's 2013 Clean Air Act to an average 6.6-percentage-point reduction in predicted cardiovascular risk.
One found PFAS mixtures associated with lower kidney filtration, with blood lipids mediating much of it. The other found the lipid association weaker in people with healthier habits.
A comparison of 2020–2025 approvals finds 94 novel oncology drugs from the NMPA against 87 from the FDA, with China's volume overtaking from 2023. The speed and first-in-class figures run the other way.
An all-oral short regimen, its length set by chest-imaging severity, was non-inferior to 18-month treatment and caused fewer serious adverse events in a Chinese randomised trial.
Guangdong recorded 25,335 local cases in 2025 — 98% of everything China has ever reported. Genomic analysis finds every Chinese outbreak lineage matching a recent import.
A 23-year genetic-network analysis of 5,094 cases identified 107 molecular super-spreaders, mostly men aged 50-69, with 94.4% living within 2 km of major transport routes.
A national case-crossover study of 236,260 chronic kidney disease deaths finds women, over-65s and people in cooler regions most affected — and projects the burden nearly quadrupling by the 2090s.
A new audit of China's regulatory record finds a market concentrated in radiology, dominated by deep learning, and clustered in four cities. It also finds the approval curve flattening.
A trial across five Chinese hospitals found remote robotic urological surgery non-inferior to local surgery. The sample is small, the surgeons were experts, and the network never failed.
SURPASS-CN-INS randomised 257 adults at 26 Chinese hospitals. The 10 mg and 15 mg doses performed almost identically against placebo, and diarrhoea affected roughly a third of those on the higher doses.